Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Draws Hope From FDA’s Fluticasone Labelling Update

Executive Summary

Mylan sees supplemental labelling updates made by the FDA for all fluticasone-based medicines as

You may also be interested in...



Mylan Launches US Advair Rival, Wixela Inhub, At A 70% Discount

Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.

Mylan Gears Up To Launch US Advair Rival This Month

Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.

Mylan’s Wixela is ‘imminent’

Mylan believes that US Food and Drug Administration (FDA) approval of its Wixela Inhub generic alternative to GlaxoSmithKline’sAdvair Diskus (fluticasone/salmeterol) respiratory blockbuster is “imminent”. “Mylan confirms it has not received any new information request or complete response letter (CRL) from the FDA,” the company said in a statement issued on 22 October.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel